Avalo Therapeutics AVTX Business Segments — Total stock-based compensation
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's business segments — total stock-based compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's business segments — total stock-based compensation?
- Avalo Therapeutics (AVTX) reported business segments — total stock-based compensation of $1.24M in Q1 2026.
- How has Avalo Therapeutics's business segments — total stock-based compensation changed year-over-year?
- Avalo Therapeutics's business segments — total stock-based compensation decreased by 4.5% year-over-year, from $1.3M to $1.24M.
- What is the long-term trend for Avalo Therapeutics's business segments — total stock-based compensation?
- Over 2 years (2023 to 2025), Avalo Therapeutics's business segments — total stock-based compensation has grown at a 113.2% compound annual growth rate (CAGR), from $1.32M to $5.99M.
- What does business segments — total stock-based compensation mean?
- Represents the non-cash expense recognized for equity-based awards granted to employees and consultants within the segment. This metric highlights the company's strategy for talent retention and alignment of employee interests with shareholder value. It is a key component of total compensation that does not impact immediate cash liquidity.